[Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
The majority of antidepressants undergo the oxidative biotransformation catalysed by cytochrome P-450, particularly by izoenzyme CYP2D6, whose activity is genetically determined. In many cases poor tolerance of antidepressants depends on CYP2D6 activity. The aim of the study was the evaluation of the relationship between the CYP2Dg genotype and the occurrence of side effects during antidepressive pharmacotherapy. Eighty nine patients were included into study. During the last episode of depression all included patients were treated with antidepressants, whose metabolism is catalysed mainly by CYP2D6. Based on medical records and patient interview the occurrence of side effects was evaluated. The genetic material was isolated from the patients' saliva. Genotyping of CYP2D6 was performed using the PCR techniques. The most frequent inactive alleles in the Caucasian population, *3 and *4 were identified. Alleles that were not identified as *3 or *4 were stated as active allele *1. Based on retrospective analysis among patients treated with antidepressants during the last episode of depression 42 patients (47.2%) reported severe side effects. Comparing to the group of patients with wide type genotype (*1/*1), in the group with the genotype including at least one inactive allele, side effects occurred significantly more frequently. In this group, comparing to the group of patients with wide type genotype, severe side effects that required discontinuation of antidepressants also occurred significantly more frequently.